MyelomA Genetics International Consortium

References

• Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860–1873.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364:1046–1060.
   PubMed Web of Science ®Google Scholar
• Becker N. Epidemiology of multiple myeloma. Recent Results Cancer Res 2011;183:25–35.
   PubMedGoogle Scholar
• Altieri A, Chen B, Bermejo JL, . Familial risks and temporal incidence trends of multiple myeloma. Eur J Cancer 2006;42:1661–1670.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Therneau TM, Rajkumar SV, . A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002;346:564–569.
   PubMed Web of Science ®Google Scholar
• Landgren O, Kristinsson SY, Goldin LR, . Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood 2009;114:791–795.
   PubMed Web of Science ®Google Scholar
• Maggini V, Buda G, Galimberti S, . Lack of association of NQO1 and GSTP1 polymorphisms with multiple myeloma risk. Leuk Res 2008;32:988–990.
   PubMed Web of Science ®Google Scholar
• Kang SH, Kim TY, Kim HY, . Protective role of CYP1A1*2A in the development of multiple myeloma. Acta Haematol 2008;119:60–64.
   PubMed Web of Science ®Google Scholar
• Kang SH, Kim TY, Kim HY, . [Association of NQO1 Polymorphism with Multiple Myeloma Risk in Koreans]. Korean J Lab Med 2006;26:71–76.
   PubMedGoogle Scholar
• Lima CS, Ortega MM, Ozelo MC, . Polymorphisms of methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MTR), methionine synthase reductase (MTRR), and thymidylate synthase (TYMS) in multiple myeloma risk. Leuk Res 2008;32:401–405.
   PubMed Web of Science ®Google Scholar
• Kim HN, Kim YK, Lee IK, . Polymorphisms involved in the folate metabolizing pathway and risk of multiple myeloma. Am J Hematol 2007;82:798–801.
   PubMed Web of Science ®Google Scholar
• Lincz LF, Scorgie FE, Kerridge I, . Methionine synthase genetic polymorphism MS A2756G alters susceptibility to follicular but not diffuse large B-cell non-Hodgkin's lymphoma or multiple myeloma. Br J Haematol 2003;120:1051–1054.
   PubMed Web of Science ®Google Scholar
• Hosgood HD 3rd, Baris D, Zhang Y, . Genetic variation in cell cycle and apoptosis related genes and multiple myeloma risk. Leuk Res 2009;33:1609–1614.
   PubMed Web of Science ®Google Scholar
• Hosgood HD 3rd, Baris D, Zhang Y, . Caspase polymorphisms and genetic susceptibility to multiple myeloma. Hematol Oncol 2008;26:148–151.
   PubMed Web of Science ®Google Scholar
• Jamroziak K, Balcerczak E, Calka K, . Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ABCB1) and risk of multiple myeloma. Leuk Res 2009;33:332–335.
   PubMed Web of Science ®Google Scholar
• Birmann BM, Tamimi RM, Giovannucci E, . Insulin-like growth factor-1- and interleukin-6-related gene variation and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev 2009;18: 282–288.
   PubMed Web of Science ®Google Scholar
• Abazis-Stamboulieh D, Oikonomou P, Papadoulis N, . Association of interleukin-1A, interleukin-1B and interleukin-1 receptor antagonist gene polymorphisms with multiple myeloma. Leuk Lymphoma 2007;48:2196–2203.
   PubMed Web of Science ®Google Scholar
• Wacholder S, Chanock S, Garcia-Closas M, . Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004;96:434–442.
   PubMed Web of Science ®Google Scholar
• Dudbridge F, Gusnanto A. Estimation of significance thresholds for genomewide association scans. Genet Epidemiol 2008;32:227–234.
   PubMed Web of Science ®Google Scholar
• International HapMap Consortium. A haplotype map of the human genome. Nature 2005;437:1299–1320.
   PubMed Web of Science ®Google Scholar
• Price AL, Patterson NJ, Plenge RM, . Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006;38:904–909.
   PubMed Web of Science ®Google Scholar
• Fletcher O, Houlston RS. Architecture of inherited susceptibility to common cancer. Nat Rev Cancer 2010;10:353–361.
   PubMed Web of Science ®Google Scholar
• Jones AV, Chase A, Silver RT, . JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 2009;41:446–449.
   PubMed Web of Science ®Google Scholar
• Olcaydu D, Harutyunyan A, Jager R, . A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 2009;41:450–454.
   PubMed Web of Science ®Google Scholar
• Kilpivaara O, Mukherjee S, Schram AM, . A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 2009;41:455–459.
   PubMed Web of Science ®Google Scholar
• Spencer CC, Su Z, Donnelly P, . Designing genome-wide association studies: sample size, power, imputation, and the choice of genotyping chip. PLoS Genet 2009;5:e1000477.
   PubMed Web of Science ®Google Scholar